Answers are grounded in this paper and cite their sources.
Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT. Preliminary results suggested a positive impact on survival. A phase III study to definitively test this neoadjuvant-concurrent strategy is warranted.
No takes yet. Share an insight, caveat, or question.
Hui et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: